Evidence map›Paper›PMID 34435935›Full record

ArticleHuman vaccines & immunotherapeutics2021

Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine.

Olivia G Cohen, Ashley K Clark, Heather Milbar, Mordechai Tarlow

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature.Clinical, cosmetic and investigational dermatology · 2022
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Olivia G CohenDepartment of Dermatology, The University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-7080-5937
Ashley K ClarkDepartment of Dermatology, The University of Pennsylvania, Philadelphia, PA, USA.
Heather MilbarDepartment of Dermatology, The University of Pennsylvania, Philadelphia, PA, USA.
Mordechai TarlowAdvanced Dermatology & Skin Surgery, PC, Lakewood, NJ, USA.
University of Pennsylvania · USAdvanced Dermatology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pityriasis rosea (PR) is an acute papulosquamous cutaneous disorder that classically presents with a herald patch rapidly followed by a widespread rash along skin cleavage lines. Although the exact pathogenesis of PR is unknown, current evidence suggests that an inflammatory reaction due to a viral trigger may lead to the cutaneous manifestations. COVID-19 has been reported as one such viral trigger for PR. Previously, PR has been reported in temporal association with various viral inoculations. This article presents a case of PR in a 66-year-old black male 1 week after administration of the Pfizer-BioNTech COVID-19 vaccine.

Indexed as

COVID-19Pityriasis RoseaAgedBNT162 VaccineHumansMaleSARS-CoV-2SkinBNT162 VaccineCOVID-19pityriasis roseaVaccination

Identifiers

PMID34435935
PMCPMC8828149
OpenAlexW3194581093

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.